Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer

News   May 24, 2012

 
Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer
 
 
 

RELATED ARTICLES

Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual Meeting

News

The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.

READ MORE

DataArt Joins Biotechnology Association BIO Deutschland

News

Global technology consultancy DataArt announced today that it has joined BIO Deutschland, Germany's biotechnology industry association.

READ MORE

Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to Treatment

News

Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE